Of the 7,000 known rare diseases, less than 10 per cent have an effective drug therapy. Of these, about 60 per cent are brought to Canada, where it can take up to an additional six years for approval versus the US or Europe.
Read MoreMONTREAL, July 4, 2024 — Mila - Quebec Artificial Intelligence Institute is pleased to announce a partnership with Sorintellis, a Montreal-based AI company whose mission is to innovate pharmaceutical portfolio management using a data-driven approach and artificial intelligence (AI) technologies.
Read MoreMontreal, QC – The Canadian Alliance for Skills and Training in Life Sciences (CASTL) announced today they have signed a memorandum of understanding (MOU) with Moderna Canada to support biomanufacturing training for employees at Moderna’s new vaccine manufacturing facility in Laval, Quebec.
Read MoreMONTREAL, February 1, 2024 – ExCellThera Inc. (ExCellThera), a world leader in enhanced blood stem cell therapies, announced today a publication in the journal Blood that further elucidates the UM171 mechanism of action and highlights the potential for UM171 to result in the efficient expansion of stem cells with preserved function for therapeutic use.
Read MoreMONTRÉAL, June 17, 2022 – ExCellThera Inc. (ExCellThera), an advanced clinical-stage biotechnology company delivering molecules and bioengineering solutions to expand and engineer various cell lines for use in next generation cell and gene therapies, announced today that it has submitted a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA) for UM171, a proprietary molecule being studied for use in the expansion and rejuvenation of hematopoietic stem cells.
Read MoreMONTREAL, July 13, 2021 – ExCellThera Inc. (ExCellThera), a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, today announced that it has entered into a licensing agreement with Astellas Pharma Inc. through its US subsidiary, Astellas Institute for Regenerative Medicine, for the in vitro use of the UM171 compound and certain other molecules in the field of pluripotent stem cells (PSCs) and PSC-derived cells.
Read MoreExCellThera Inc., a clinical-stage molecular medicine company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that it has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency (EMA) for ExCellThera’s most advanced technology, ECT-001 Cell Therapy.
Read MoreIRICoR, a Centre of Excellence in Commercialization and Research with a focus on drug discovery, announces a new investment in ExCellThera Inc., a clinical-stage cell and molecular medicine company which it co-founded in 2015.
Read MoreExCellThera Inc., an advanced biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that data from a Phase I/II clinical trial using its lead technology, ECT-001, will be presented at the 61st Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida.
Read More